O Sitbon

Summary

Country: France

Publications

  1. ncbi request reprint Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension
    Vincent Castelain
    Department of Pulmonary Medicine UPRES 2705, Antoine Béclère Teaching Hospital, Clamart, France
    Am J Respir Crit Care Med 165:338-40. 2002
  2. doi request reprint Optimal management of severe pulmonary arterial hypertension
    O Sitbon
    Universite Paris Sud 11, Faculte de Medecine, Le Kremlin Bicetre, France
    Eur Respir Rev 20:254-61. 2011
  3. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
  4. ncbi request reprint Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    O Sitbon
    Hopital Antoine Beclere, Service de Pneumologie, Clamart, France
    Eur J Clin Invest 36:25-31. 2006
  5. ncbi request reprint [Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]
    O Sitbon
    Centre de référence national sur l HTAP, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Hopital Antoine Beclere, AP HP, Clamart
    Presse Med 34:1456-64. 2005
  6. ncbi request reprint Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    Olivier Sitbon
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, AP HP, Universite Paris Sud, Clamart, France
    Circulation 111:3105-11. 2005
  7. ncbi request reprint Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Cardiovasc Pharmacol 49:1-5. 2007
  8. ncbi request reprint Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era
    Olivier Sitbon
    Service de Pneumologie Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Am J Respir Crit Care Med 177:108-13. 2008
  9. ncbi request reprint [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]
    Olivier Sitbon
    Centre de référence national de l HTAP, Service de Pneumologie, UPRES EA2705, Hopital Antoine Beclere, AP HP, Université Paris XI Sud, 92141 Clamart Cedex, France
    Rev Prat 58:2011-8. 2008
  10. ncbi request reprint [Treatment goals in pulmonary arterial hypertension]
    Laurent Savale
    Universite Paris Sud XI, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 39:1S33-40. 2010

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi request reprint Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension
    Vincent Castelain
    Department of Pulmonary Medicine UPRES 2705, Antoine Béclère Teaching Hospital, Clamart, France
    Am J Respir Crit Care Med 165:338-40. 2002
    ..1 mm Hg/L/min/m(2) (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise...
  2. doi request reprint Optimal management of severe pulmonary arterial hypertension
    O Sitbon
    Universite Paris Sud 11, Faculte de Medecine, Le Kremlin Bicetre, France
    Eur Respir Rev 20:254-61. 2011
    ..We also review treatment strategies that may offer clinical benefits to patients with more severe PAH...
  3. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
    ..A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations...
  4. ncbi request reprint Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    O Sitbon
    Hopital Antoine Beclere, Service de Pneumologie, Clamart, France
    Eur J Clin Invest 36:25-31. 2006
    ..Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD)...
  5. ncbi request reprint [Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]
    O Sitbon
    Centre de référence national sur l HTAP, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Hopital Antoine Beclere, AP HP, Clamart
    Presse Med 34:1456-64. 2005
    ..The Pulmonary Vascular Diseases working group of the French Society of Pulmonary Medicine has developed guidelines for the best practices in use of these drugs...
  6. ncbi request reprint Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    Olivier Sitbon
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, AP HP, Universite Paris Sud, Clamart, France
    Circulation 111:3105-11. 2005
    ..Characteristics of patients with idiopathic pulmonary arterial hypertension (IPAH) who benefit from long-term calcium channel blockers (CCB) are unknown...
  7. ncbi request reprint Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Cardiovasc Pharmacol 49:1-5. 2007
    ..Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol...
  8. ncbi request reprint Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era
    Olivier Sitbon
    Service de Pneumologie Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Am J Respir Crit Care Med 177:108-13. 2008
    ..The prevalence of HIV-associated pulmonary arterial hypertension (PAH) has not been evaluated since introduction of combined, highly active antiretroviral treatments...
  9. ncbi request reprint [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]
    Olivier Sitbon
    Centre de référence national de l HTAP, Service de Pneumologie, UPRES EA2705, Hopital Antoine Beclere, AP HP, Université Paris XI Sud, 92141 Clamart Cedex, France
    Rev Prat 58:2011-8. 2008
    ..However, their prognosis differs greatly: it is poor in scleroderma, and much better in congenital heart diseases...
  10. ncbi request reprint [Treatment goals in pulmonary arterial hypertension]
    Laurent Savale
    Universite Paris Sud XI, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 39:1S33-40. 2010
    ..The impact of these new therapeutic approaches on long-term survival of patients with PAH is a major challenge in the near future...
  11. pmc Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Thorax 60:1025-30. 2005
    ....
  12. doi request reprint Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals
    O Sitbon
    Hopital Antoine Beclere, Universite Paris Sud 11, Clamart, France
    Eur Respir Rev 19:272-8. 2010
    ..Future refinement of goal-oriented therapy could include the use of multiple prognostic markers, while additional, large clinical trials will answer questions concerning choice and combination of treatment goals...
  13. ncbi request reprint [Pulmonary artery hypertension associated with connective tissue diseases]
    O Sanchez
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart
    Presse Med 32:789-99. 2003
    ..In our centre of pulmonary vascular diseases, connective tissue diseases represent the third cause of PH...
  14. ncbi request reprint Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
    R Souza
    Université Pains Sud, UPRES EA 2705 Pneumology Dept and French National Reference Centre for Pulmonary Hypertension, Antoine Beclere Hospital, Clamart, Paris, France
    Eur Respir J 31:343-8. 2008
    ..Therefore, the present authors conclude that fenfluramine exposure characterises a potent trigger for pulmonary arterial hypertension without influencing its clinical course...
  15. ncbi request reprint Risk factors for pulmonary arterial hypertension
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Clin Chest Med 22:459-75. 2001
    ....
  16. doi request reprint The association between resting and mild-to-moderate exercise pulmonary artery pressure
    K Whyte
    Service des Explorations Fonctionnelles, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92 140, Clamart, France
    Eur Respir J 39:313-8. 2012
    ..The clinical relevance of such findings deserves further long-term follow-up studies...
  17. ncbi request reprint [Treatments for pulmonary arterial hypertension]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Rev Med Interne 25:720-31. 2004
    ..We here present the different therapeutic alternatives available in the PAH and propose an algorithm for treatment of these patients...
  18. doi request reprint Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
    B Degano
    Department of Respiratory and Intensive Care Medicine, Universite Paris Sud 11, National Reference Centre for Pulmonary Arterial Hypertension, Institut Paris Sud Cytokines, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 33:92-8. 2009
    ..The present data confirm the long-term benefits of bosentan therapy in HIV-associated pulmonary arterial hypertension patients with improvements in symptoms, 6-min walk distance and haemodynamics, and with favourable overall survival...
  19. ncbi request reprint Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
    S Provencher
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 32:393-8. 2008
    ..Improvement in exercise tolerance with chronic therapy is independently related to improvement in pulmonary haemodynamics measured in exercise but not in resting conditions...
  20. ncbi request reprint [Treatment of pulmonary arterial hypertension]
    D Montani
    Centre de référence national sur l HTAP, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Hopital Antoine Beclere, AP HP, Clamart
    Presse Med 34:1445-55. 2005
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  21. doi request reprint Pulmonary veno-occlusive disease
    D Montani
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Department of Pneumology and Intensive Care, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Eur Respir J 33:189-200. 2009
    ..Lung transplantation is the treatment of choice. Cautious use of specific PAH therapy can, however, be helpful in some patients...
  22. ncbi request reprint Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
    D Montani
    Universite Paris Sud, Faculte de Medecine, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, AP HP, INSERM U999, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 34:1348-56. 2009
    ..Cautious use of continuous intravenous epoprostenol improved clinical and haemodynamic parameters in PVOD patients at 3-4 months without commonly causing pulmonary oedema, and may be a useful bridge to urgent lung transplantation...
  23. doi request reprint [Guidelines for the diagnosis and treatment of pulmonary hypertension]
    O Sanchez
    Service de Pneumologie et Soins Intensifs, Hopital Europeen Georges Pompidou, AP HP, Faculte de Medecine, Universite Paris Descartes, 20, rue Leblanc, 75015 Paris, France
    Rev Mal Respir 27:141-50. 2010
    ..A joint Task Force of the ESC and of the ERS has developed guidelines on the diagnosis and treatment of pulmonary hypertension (PH) to provide updated information on the management of patients with this condition...
  24. ncbi request reprint [Pulmonary arterial hypertension]
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique, Hopitaux de Paris, Clamart, France
    Rev Mal Respir 22:651-66. 2005
    ..Pulmonary arterial hypertension (PAH) is a rare condition characterised by progressively elevated pulmonary arterial resistance leading to right heart failure...
  25. doi request reprint Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 36:549-55. 2010
    ..Survival of idiopathic, familial and anorexigen-associated PAH can be characterised by means of a novel risk-prediction equation using patients' characteristics at diagnosis...
  26. ncbi request reprint Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
    B Sztrymf
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique, Hopitaux de Paris, 92140 Clamart, France
    Eur Respir J 35:1286-93. 2010
    ..Whether these parameters can guide therapy needs to be further investigated...
  27. ncbi request reprint [Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension]
    B Sztrymf
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Paris, France
    Rev Mal Respir 21:909-15. 2004
    ..It seems important to compare the idiopathic form of PAH with these familial forms to confirm that the same diagnostic and therapeutic principles can be applied to familial PAH...
  28. ncbi request reprint Pathobiology of pulmonary hypertension. The role of platelets and thrombosis
    P Herve
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine Béclère et Hôpital Marie Lannelongue, Universite Paris Sud, Clamart, France
    Clin Chest Med 22:451-8. 2001
    ..Activated platelets interact with the PA wall and may contribute to the functional and structural alterations of pulmonary vessels by releasing vasoactive factors and mitogenic mediators...
  29. ncbi request reprint [Pulmonary arterial hypertension due to tumor emboli]
    J M Dot
    Centre national de référence de l hypertension pulmonaire, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Rev Mal Respir 24:359-66. 2007
    ..Pulmonary arterial hypertension (PAH) is rare in the presence of malignancy and tumour embolisation is one of several possible pathological mechanisms...
  30. ncbi request reprint [Postembolic pulmonary hypertension]
    X Jais
    Centre de Référence de l Hypertension Artérielle Pulmonaire, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    Rev Mal Respir 24:497-508. 2007
    ..The consequence is an increase in pulmonary vascular resistance resulting in pulmonary hypertension (PH) and progressive right heart failure...
  31. ncbi request reprint [Pulmonary hypertension associated with connective tissue diseases]
    O Sanchez
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92141 Clamart, France
    Rev Med Interne 23:41-54. 2002
    ..So, we observed dramatic improvement in rare cases after immunosuppressive therapy...
  32. ncbi request reprint Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
    J Le Pavec
    Hopital Marie Lannelongue, Universite Paris Sud, Le Plessis Robinson, France
    Eur Respir J 34:731-9. 2009
    ..Biliary cirrhosis induces pulmonary vasodilation that ameliorates MCT-induced PH and improves survival. Upregulation of inducible NO synthase and ET(B) receptor and downregulation of ET(A) receptor may be involved...
  33. ncbi request reprint Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
    D Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Eur Respir J 26:969-72. 2005
    ..In conclusion, further studies should help in characterising the best candidates for anti-inflammatory treatment in the setting of pulmonary arterial hypertension...
  34. ncbi request reprint Occult alveolar haemorrhage in pulmonary veno-occlusive disease
    A Rabiller
    Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Eur Respir J 27:108-13. 2006
    ..It was concluded that occult alveolar haemorrhage is a common feature of pulmonary veno-occlusive disease. Detecting occult alveolar haemorrhage may be of interest in the diagnostic approach of pulmonary veno-occlusive disease...
  35. ncbi request reprint Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension
    L C Price
    Faculte de Medecine, University Paris Sud, Kremlin Bicetre, France
    Eur Respir J 35:1294-302. 2010
    ..Emergency procedures, major surgery and long operations were associated with increased risk...
  36. doi request reprint HIV-related pulmonary arterial hypertension: clinical presentation and management
    Olivier Sitbon
    National Reference Center for Pulmonary Hypertension, Hopital Antoine Beclere, Clamart, France
    AIDS 22:S55-62. 2008
    ..Taking into account currently available data and clinical experience, a treatment algorithm for HIV-PAH based on that defined in treatment guidelines for other forms of PAH is suggested...
  37. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  38. pmc Splenectomy and chronic thromboembolic pulmonary hypertension
    X Jais
    UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Thorax 60:1031-4. 2005
    ....
  39. ncbi request reprint Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension
    S Gunther
    Universite Paris Sud, Hopital de Bicetre, AP HP, Le Kremlin Bicetre, France
    Arthritis Rheum 64:2995-3005. 2012
    ..No HRCT data are available on SSc patients with precapillary PH. We undertook this study to evaluate the frequency and effect on prognosis of HRCT signs of PVOD in SSc patients with precapillary PH...
  40. doi request reprint [HIV-related pulmonary arterial hypertension]
    L Savale
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, France
    Rev Mal Respir 29:491-500. 2012
    ..Other PAH-specific therapies remain to be evaluated. The advent of HAART associated with the development of PAH-specific therapies has improved the prognosis of patients HIV-related PAH, with a survival rate of about 70% at 3 years...
  41. pmc Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
    H Nunes
    UPRES EA 2363, Service de Pneumologie, Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris 13, 125 rue de Stalingrad, 93009 Bobigny, France
    Thorax 61:68-74. 2006
    ..Pulmonary hypertension (PH) is a rare complication of sarcoidosis, although it is not uncommon in advanced disease...
  42. ncbi request reprint [Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]
    R Azarian
    Service de Pneumologie, , Clamart
    Arch Mal Coeur Vaiss 87:1709-13. 1994
    ..Chronic thromboembolism should be systematically investigated as the cause of pulmonary hypertension considering that in selected cases, curative surgery is possible...
  43. ncbi request reprint Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
    S Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud IX, Hopital Antoine Beclere, Clamart, France
    Eur Respir J 27:114-20. 2006
    ..The lack of chronotropic response may reflect the loss in normal physiological reserve in more unwell patients...
  44. doi request reprint Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre
    D Montani
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, AP HP, Centre National de Référence de l Hypertension Pulmonaire Sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Clamart
    Eur Respir Rev 18:272-90. 2009
    ..Appropriate investigation and therapeutic strategies for patients with chronic thromboembolic disease and PH that is associated with congenital heart disease, pulmonary veno-occlusive disease and systemic sclerosis are also highlighted...
  45. doi request reprint Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
    David Montani
    Universite Paris Sud, Orsay, France
    Adv Ther 26:813-25. 2009
    ..Due to their clinical effectiveness, tolerance profile, and their oral administration, sildenafil and tadalafil are two of the recommended first-line therapies for PAH patients in World Health Organization functional classes II or III...
  46. ncbi request reprint Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
    Olivier Sitbon
    Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 40:780-8. 2002
    ..We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion...
  47. ncbi request reprint BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
    M Humbert
    Service de Pneumologie, Hĵpital Antoine Béclère, Clamart, France
    Eur Respir J 20:518-23. 2002
    ....
  48. ncbi request reprint [Genetics of pulmonary arterial hypertension: recent data and practical applications]
    B Sztrymf
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Rev Mal Respir 22:796-805. 2005
    ..Beside idiopathic PAHT and that associated with other conditions, a familial form has been identified...
  49. ncbi request reprint [Pulmonary artery hypertension: therapeutic progress]
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Hopital Antoine Beclere, Clamart
    Rev Mal Respir 20:S26-33. 2003
  50. ncbi request reprint Primary pulmonary hypertension: Current therapy
    Olivier Sitbon
    Service de Pneumologie et Reanimation Respiratoire, Pulmonary Vascular Center, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Prog Cardiovasc Dis 45:115-28. 2002
    ..In such patients with severe pulmonary hypertension refractory to medical therapy, atrioseptostomy and lung transplantation can be indicated...
  51. ncbi request reprint [Pulmonary hypertension associated with systemic sclerosis]
    Olivier Sanchez
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Ann Med Interne (Paris) 153:250-9. 2002
    ..Novel therapies including oral, sub-cutaneous or inhaled stable prostacyclin analogues and endothelin receptor antagonists are currently evaluated in large placebo-controlled trials...
  52. doi request reprint Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicêtre F 94276, France
    Respir Med 104:S74-80. 2010
    ..This review details the rationale for the different combination strategies and examines the clinical evidence in favour of some of the approaches that have been evaluated...
  53. ncbi request reprint Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension
    Hilario Nunes
    UPRES 2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 167:1433-9. 2003
    ..These results suggest that patients with severe human immunodeficiency virus-associated PAH should be considered for long-term epoprostenol infusion in association with CART...
  54. ncbi request reprint [Therapeutic management of porto-pulmonary hypertension. Complication of portal hypertension: how to treat pleuro-pulmonary complications?]
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Assistance Publique, Hopitaux de Paris, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92141 Clamart
    Rev Mal Respir 21:637-43. 2004
  55. ncbi request reprint Fenfluramine-like cardiovascular side-effects of benfluorex
    K Boutet
    Université Paris Sud11, UPRES EA 2705, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Paris, France
    Eur Respir J 33:684-8. 2009
    ....
  56. doi request reprint Fatal dissection of the pulmonary artery in pulmonary arterial hypertension
    B Degano
    Universite Paris Sud, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Hopital Antoine Beclere, Clamart, France
    Eur Respir Rev 18:181-5. 2009
    ..In addition, better identification of the risk factors for pulmonary artery dissection may help in considering transplantation for selected patients at risk...
  57. ncbi request reprint [Pulmonary hypertension and obesity]
    B Sztrymf
    Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Hopital Antoine Béclere AP HP, Universite Paris Sud, 157, rue de la Porte de Trivaux, 92140 Clamart
    Rev Pneumol Clin 58:104-10. 2002
    ..There is also a possible relationship with left ventricular failure, hypoxemia, and other respiratory disorders (including obstructive sleep apnea), hypothyroidism, and thomboembolism...
  58. ncbi request reprint Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences
    David Montani
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Semin Respir Crit Care Med 30:411-20. 2009
    ..Lung transplantation remains the treatment of choice, but cautious use of specific PAH therapy can be helpful in select patients while awaiting this intervention...
  59. ncbi request reprint Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension
    Ségolène Cabrol
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Heart Lung Transplant 26:357-62. 2007
    ..Vascular remodeling lesions can be found in lungs of patients with CTEPH. Little is known about epoprostenol therapy in inoperable distal CTEPH patients...
  60. ncbi request reprint Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
    Olivier Sitbon
    Service de Pneumologie Réanimation Respiratoire, Hopital Antoine Beclere, 157, Avenue de la Porte Trivaux, F 92141 Clamart Cedex, France
    Chest 124:247-54. 2003
    ..We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH)...
  61. ncbi request reprint Pulmonary arterial hypertension and HIV infection
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France
    Semin Respir Crit Care Med 30:440-7. 2009
    ..Other PAH therapies, including prostacyclin analogs, type 5 phosphodiesterase inhibitors, and single endothelin receptor antagonists, have yet to be evaluated in PAH-HIV...
  62. doi request reprint Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology
    David Montani
    Universite Paris Sud 11, UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Paris, France
    Medicine (Baltimore) 87:220-33. 2008
    ..Clinical outcomes of PVOD patients were worse than those of PAH patients...
  63. doi request reprint [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]
    David Montani
    Univ Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Presse Med 39:134-43. 2010
    ..In patients with the most severe disease, the prudent use of continuous intravenous epoprostenol, can serve as bridge-therapy while awaiting a lung transplant...
  64. ncbi request reprint Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
    ..Because they are generally excluded from randomized controlled trials, little is known about these patients...
  65. doi request reprint HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
    Bruno Degano
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    AIDS 24:67-75. 2010
    ....
  66. doi request reprint Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010
    ..We conducted a study to characterize mortality in a multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension in the modern management era...
  67. doi request reprint [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 40:1S54-60. 2011
    ..Finally, clinical trials evaluating combinations of treatments have shown encouraging results...
  68. ncbi request reprint [Pulmonary arterial hypertension]
    Xavier Jais
    Centre de référence de l hypertension pulmonaire sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 92141 Clamart Cedex, France
    Rev Prat 58:1997-2010. 2008
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  69. ncbi request reprint Pulmonary arterial hypertension in France: results from a national registry
    Marc Humbert
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 173:1023-30. 2006
    ..Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach...
  70. ncbi request reprint Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    N Engl J Med 351:1425-36. 2004
  71. ncbi request reprint Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases
    Xavier Jais
    Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Arthritis Rheum 58:521-31. 2008
    ..To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD)...
  72. ncbi request reprint Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
    Olivier Sitbon
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 170:1212-7. 2004
    ....
  73. doi request reprint Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?
    Dermot S O'Callaghan
    Faculte de Medecine, Universite Paris Sud, 94276 Kremlin Bicêtre, France
    Presse Med 40:e65-78. 2011
    ..This review summarises the epidemiologic, clinico-pathologic and imaging characteristics of PVOD in the setting of CTD and discusses potential management approaches...
  74. ncbi request reprint Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
    M Humbert
    Unité Propre de Recherche de l Enseignement Supérieur 2705, Centre des Maladies Vasculaires Pulmonaires, Hĵpital Antoine Béclère, Universite Paris Sud, Clamart, France
    Eur Respir J 20:59-65. 2002
    ..4 nmol x L(-1)). It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension...
  75. ncbi request reprint [Treatment of porto pulmonary hypertension]
    Olivier Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation, UPRES EA2705, Universite Paris Sud, Assistance Publique, Hopitaux de Paris, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92141 Clamart
    Gastroenterol Clin Biol 28:B312-6. 2004
  76. ncbi request reprint Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation
    Barbara Girerd
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, 92140 Clamart, France
    Am J Respir Crit Care Med 181:851-61. 2010
    ..Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH)...
  77. ncbi request reprint Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP Université Paris Sud, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Heart J 27:589-95. 2006
    ..Data on long-term efficacy of bosentan in unselected idiopathic pulmonary arterial hypertension (IPAH) patients are lacking. We aimed to describe the long-term outcome of consecutive IPAH patients treated first-line with bosentan...
  78. doi request reprint Pulmonary veno-occlusive disease: recent progress and current challenges
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U999, Centre National de Référence de l Hypertension Pulmonaire Sévère, 92140 Clamart, France
    Respir Med 104:S23-32. 2010
    ..Unfortunately, the long term effects of these agents are variable and lung transplantation remains the treatment of choice...
  79. ncbi request reprint Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure
    Arnaud Resten
    Department of Radiology, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Radiology 222:782-8. 2002
    ..To correlate pretherapeutic thin-section computed tomographic (CT) findings in patients with pulmonary hypertension with the risk of fatality with treatment with epoprostenol...
  80. ncbi request reprint Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Gastroenterology 130:120-6. 2006
    ..The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding...
  81. ncbi request reprint Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
    Steeve Provencher
    Service de Pneumologie et Réanimation Hôpital Antoine Béclère, Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, AP HP Université Paris Sud, Clamart, France
    Expert Opin Pharmacother 6:1337-48. 2005
    ..In the present report, the pharmacology, clinical efficacy and safety profile of bosentan are summarised. The place of bosentan among the current therapies available for the treatment of PAH is also discussed...
  82. ncbi request reprint Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension
    Olivier Sanchez
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Chest 130:182-9. 2006
    ..Immunosuppressive therapy should be better evaluated in this setting.Study design: Monocentric retrospective study...
  83. ncbi request reprint Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease
    Arnaud Resten
    Service de Radiologie, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, Clamart 92140, France
    AJR Am J Roentgenol 183:65-70. 2004
    ..The aim of our study was to evaluate this disease noninvasively using CT of the chest...
  84. ncbi request reprint Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation
    Benjamin Sztrymf
    Universite Paris Sud 11, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:1377-83. 2008
    ..Germline mutations in the gene encoding for bone morphogenetic protein receptor 2 (BMPR2) are a cause of pulmonary arterial hypertension (PAH)...
  85. ncbi request reprint Portopulmonary hypertension: survival and prognostic factors
    Jerome Le Pavec
    Universite Paris Sud 11, UPRES 2705, Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 178:637-43. 2008
    ..Survival results in PoPH are contrasting, and prognostic factors need to be identified...
  86. ncbi request reprint Idiopathic pulmonary hypertension: what did we learn from genes?
    Benjamin Sztrymf
    UPRES 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Sarcoidosis Vasc Diffuse Lung Dis 22:S91-100. 2005
    ..Nevertheless, PAH pathobiology remains unclear and genomic approaches may identify additional molecular determinants for this disorder...
  87. ncbi request reprint [Chronic post-embolic pulmonary artery hypertension]
    Colas Tcherakian
    Centre de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, UPRES EA2705, Hopital Antoine Beclere, 92141 Clamart Cedex
    Rev Prat 57:747-8. 2007
  88. ncbi request reprint Pulmonary vascular abnormalities in cirrhosis
    Philippe Herve
    National French Reference Centre for Pulmonary Arterial Hypertension, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Best Pract Res Clin Gastroenterol 21:141-59. 2007
    ..Resolution of HPS is common after liver transplantation, which has an uncertain effect in POPH...
  89. ncbi request reprint Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Curr Opin Pulm Med 16:S21-6. 2010
    ..Treatment goals need to be carefully defined in order to correctly measure whether a treatment is successful and indicate when additional treatment is required...
  90. doi request reprint Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure
    Delphine Natali
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Chest 140:1066-8. 2011
    ..In this case report, we hypothesize that PTEN mutations may be a predisposing factor for the development of PAH, with anorexigen exposure as a potential trigger...
  91. ncbi request reprint Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UP RES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud XI, Hopital Antoine Beclere, Clamart, France
    Chest 128:622S-628S. 2005
    ..Early detection and adequate clinical classification of the disease, better assessment of patients' prognosis, and improved therapeutic strategies are important challenges for clinicians in coming years...
  92. ncbi request reprint Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases
    Martine Bonnin
    Department of Anesthesiology and Intensive Care, Antoine Beclere Hospital Assistance Publique des Hôpitaux de Paris APHP, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, BP 405, France
    Anesthesiology 102:1133-7; discussion 5A-6A. 2005
    ..Available literature on pregnant women with severe pulmonary hypertension (PH) relies mainly on anecdotal case reports and two series only...
  93. ncbi request reprint Automatic quantification of right ventricular function with gated blood pool SPECT
    Doumit Daou
    Department of Nuclear Medicine, Lariboisiere University Hospital, AP HP, Paris, France
    J Nucl Cardiol 11:293-304. 2004
    ..In parallel, we compared the RVEF, RV end-diastolic volume (EDV), and RV end-systolic volume (ESV) provided by QBS and GBPS(35%)...
  94. doi request reprint Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
    David Launay
    Universite Paris Sud, Faculte de Medecine, Kremlin Bice tre, France
    Rheumatology (Oxford) 49:490-500. 2010
    ..We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of prostanoids or sildenafil...
  95. ncbi request reprint Prostanoid therapy for pulmonary arterial hypertension
    David B Badesch
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Coll Cardiol 43:56S-61S. 2004
    ..In conclusion, though treatment with prostanoids is complicated by their generally short half-lives and complicated drug delivery systems, they continue to play an important role in the treatment of PAH...
  96. ncbi request reprint Endothelin receptor antagonists in pulmonary arterial hypertension
    Richard N Channick
    Pulmonary and Critical Care Division, University of California, San Diego, California, USA
    J Am Coll Cardiol 43:62S-67S. 2004
    ..The selective endothelin receptor-A antagonists sitaxsentan and ambrisentan are currently undergoing investigation...
  97. ncbi request reprint Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France
    David Montani
    AIDS 19:1239-40. 2005
  98. ncbi request reprint Inhaled iloprost for severe pulmonary hypertension
    Horst Olschewski
    Department of Internal Medicine II, University Clinic, Giessen, Germany
    N Engl J Med 347:322-9. 2002
    ..Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension...
  99. ncbi request reprint Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    J Am Coll Cardiol 39:1496-502. 2002
    ....
  100. ncbi request reprint Diagnosis and differential assessment of pulmonary arterial hypertension
    Robyn J Barst
    Columbia University College of Physicians and Surgeons, New York, New York, USA
    J Am Coll Cardiol 43:40S-47S. 2004
    ..Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy...
  101. ncbi request reprint Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension
    Rajiv D Machado
    Division of Medical Genetics, Department of Genetics, University of Leicester, Leicester, United Kingdom
    Hum Mutat 27:121-32. 2006
    ....